| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/EURHEARTJ/EHT271 |
| P698 | PubMed publication ID | 23864132 |
| P50 | author | Gerhard Rogler | Q64750687 |
| P2093 | author name string | Giuseppe Rosano | |
| P2860 | cites work | Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease | Q24601951 |
| A human gut microbial gene catalogue established by metagenomic sequencing | Q24618931 | ||
| Structure, function and diversity of the healthy human microbiome | Q24626370 | ||
| An obesity-associated gut microbiome with increased capacity for energy harvest | Q27860515 | ||
| Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis | Q28259055 | ||
| The gut microbiota shapes intestinal immune responses during health and disease | Q29547727 | ||
| The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice | Q29614457 | ||
| Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome | Q29617424 | ||
| Obesity and the human microbiome | Q30052740 | ||
| Exposure to environmental microorganisms and childhood asthma | Q31000265 | ||
| Atherosclerosis, inflammation and Chlamydia pneumoniae | Q33772514 | ||
| Low doses of lipopolysaccharide and minimally oxidized low-density lipoprotein cooperatively activate macrophages via nuclear factor kappa B and activator protein-1: possible mechanism for acceleration of atherosclerosis by subclinical endotoxemia | Q33997331 | ||
| Alterations in the gut microbiome of children with severe ulcerative colitis | Q34101549 | ||
| Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease | Q34241773 | ||
| Immune cell Toll-like receptor 4 is required for cardiac myocyte impairment during endotoxemia | Q47929295 | ||
| Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease | Q48703185 | ||
| Alteration of histamine, serotonin and primary prostaglandin in case of diarrhea induced by endotoxin and gastrointestinal absorption of drug | Q50206103 | ||
| Toll-like receptor 4 mediates oxidized LDL-induced macrophage differentiation to foam cells. | Q50526173 | ||
| Potential association of Helicobacter cinaedi with atrial arrhythmias and atherosclerosis. | Q50969355 | ||
| Cellular endotoxin desensitization in patients with severe chronic heart failure. | Q54481049 | ||
| Endotoxin and immune activation in chronic heart failure: a prospective cohort study. | Q55033086 | ||
| Lipopolysaccharide induces endothelial cell apoptosis via activation of Na(+)/H(+) exchanger 1 and calpain-dependent degradation of Bcl-2 | Q56768645 | ||
| The core gut microbiome, energy balance and obesity | Q57012032 | ||
| Tumor Necrosis Factor Soluble Receptors in Patients With Various Degrees of Congestive Heart Failure | Q57951046 | ||
| Decreased intestinal CYP3A in celiac disease: Reversal after successful gluten-free diet: A potential source of interindividual variability in first-pass drug metabolism* | Q58812433 | ||
| Phagocyte-derived catecholamines enhance acute inflammatory injury | Q59082332 | ||
| Toll-like Receptor 4 Polymorphisms and Atherogenesis | Q59273869 | ||
| Are patients with inflammatory bowel disease at increased risk of coronary artery disease? | Q34290766 | ||
| Myocardial dysfunction in septic shock: Part I. Clinical manifestation of cardiovascular dysfunction | Q34293378 | ||
| IMG/M-HMP: a metagenome comparative analysis system for the Human Microbiome Project | Q34335972 | ||
| Myocardial dysfunction in septic shock: Part II. Role of cytokines and nitric oxide | Q34337261 | ||
| Alterations in diversity of the oral microbiome in pediatric inflammatory bowel disease | Q34398545 | ||
| The importance of the gastrointestinal system in the pathogenesis of heart failure | Q34429097 | ||
| Gut microbiome, obesity, and metabolic dysfunction | Q34629745 | ||
| The emerging role of the gut in chronic heart failure | Q34805115 | ||
| Toll-like receptor-mediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-activated receptor γ coactivator-1 signaling | Q35129034 | ||
| Inflammatory mediators in chronic heart failure: an overview | Q35582235 | ||
| Adiponectin attenuates lipopolysaccharide-induced acute lung injury through suppression of endothelial cell activation | Q35658773 | ||
| Chlamydia pneumoniae--an infectious risk factor for atherosclerosis? | Q35701591 | ||
| Intestinal microbiota determine severity of myocardial infarction in rats | Q35863790 | ||
| Infection as a risk factor for infarction and atherosclerosis | Q36845622 | ||
| Symbiotic gut microbes modulate human metabolic phenotypes | Q36883096 | ||
| The gut and intestinal bacteria in chronic heart failure | Q37370227 | ||
| Statin regulation of CYP3A4 and CYP3A5 expression | Q37521064 | ||
| The microbiome and obesity: is obesity linked to our gut flora? | Q37554884 | ||
| Toll-like receptor 4 stimulation initiates an inflammatory response that decreases cardiomyocyte contractility | Q37815210 | ||
| The developing intestinal microbiome and its relationship to health and disease in the neonate | Q37859258 | ||
| Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial | Q37868604 | ||
| Detection of Chlamydiae pneumoniae but not Helicobacter pylori DNA in atherosclerosis plaques | Q37869369 | ||
| Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). | Q37871321 | ||
| Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis | Q37875835 | ||
| Chronic infections and coronary heart disease: is there a link? | Q37882245 | ||
| Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group | Q37882250 | ||
| Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors | Q37886448 | ||
| Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction | Q37899465 | ||
| Developmental origins of obesity: early feeding environments, infant growth, and the intestinal microbiome | Q37989398 | ||
| Lipopolysaccharide and interferon-gamma enhance Fas-mediated cell death in mouse vascular endothelial cells via augmentation of Fas expression | Q40075367 | ||
| Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response | Q40217414 | ||
| Gastric intramucosal pH as a therapeutic index of tissue oxygenation in critically ill patients | Q41089036 | ||
| The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus | Q41212001 | ||
| Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans | Q41456111 | ||
| Synergism between melatonin and atorvastatin against endothelial cell damage induced by lipopolysaccharide | Q42735728 | ||
| Protection from lipopolysaccharide-induced pulmonary microvascular endothelial cell injury by activation of hedgehog signaling pathway | Q42791884 | ||
| Chlamydia pneumoniae and atherosclerosis: current state and future prospectives | Q43414627 | ||
| Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. | Q44301895 | ||
| The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome 'at-risk' population | Q44931040 | ||
| Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis | Q45019303 | ||
| Intestinal permeability and vitamin A absorption in patients with chemotherapy-induced diarrhea. | Q46211571 | ||
| Lipopolysaccharide downregulates CD91/low-density lipoprotein receptor-related protein 1 expression through SREBP-1 overexpression in human macrophages | Q46676720 | ||
| Altered intestinal function in patients with chronic heart failure | Q46951231 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 426-430 | |
| P577 | publication date | 2013-07-17 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | The heart and the gut. | |
| P478 | volume | 35 |
| Q41104304 | Associations of Acid Suppressive Therapy With Cardiac Mortality in Heart Failure Patients |
| Q37232667 | Associations of Bowel Movement Frequency with Risk of Cardiovascular Disease and Mortality among US Women |
| Q42376085 | Bacterial translocation and in vivo assessment of intestinal barrier permeability in rainbow trout (Oncorhynchus mykiss) with and without soyabean meal-induced inflammation |
| Q48746940 | Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study |
| Q90361660 | Blood Microbiota Modification After Myocardial Infarction Depends Upon Low-Density Lipoprotein Cholesterol Levels |
| Q35197222 | Cardiovascular complications in inflammatory bowel disease. |
| Q35470652 | Current and future trends in biomarker discovery and development of companion diagnostics for arthritis. |
| Q36318399 | Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure |
| Q104286628 | Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review |
| Q90034560 | Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease |
| Q55252106 | Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? |
| Q58854099 | Inflammatory biomarkers and effect of exercise on functional capacity in patients with heart failure: Insights from a randomized clinical trial |
| Q35034335 | Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure |
| Q41200031 | Intravital microscopy - A novel tool in characterizing congestive heart failure in experimental autoimmune myocarditis |
| Q48251451 | Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients. |
| Q58565621 | Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis |
| Q41686252 | Novel Concept of a Heart-Gut Axis in the Pathophysiology of Heart Failure |
| Q58739842 | Novel biochemical predictors of unfavorable prognosis for stable coronary disease |
| Q61851720 | Occult blood in faeces is associated with all-cause and non-colorectal cancer mortality |
| Q38676886 | Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC |
| Q39165266 | Pathophysiology of heart failure and frailty: a common inflammatory origin? |
| Q93163334 | The Lipid Paradox is present in ST-elevation but not in non-ST-elevation myocardial infarction patients: Insights from the Singapore Myocardial Infarction Registry |
| Q34474989 | The dormant blood microbiome in chronic, inflammatory diseases |
| Q64927277 | The heart-gut axis: new target for atherosclerosis and congestive heart failure therapy. |
| Q35538922 | The intestinal microbiota: its role in health and disease |
Search more.